Trial Profile
A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125 in HIV-1 Infected Subjects With Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Etravirine (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Therapeutic Use
- Sponsors Janssen R&D Ireland
- 21 Jul 2009 Actual patient number changed from 199 to 211 as reported by ClinicalTrials.gov.
- 10 Mar 2009 New trial record.
- 28 Jan 2009 Results were published in AIDS.